GlassScriptPhysician profile
Rachel C Cittone
NPI 1275704801
$2,623.58
in general payments reported to CMS, 2019-2025
24 companies · $983 in 2025
The $983 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $119 · 2023: $628 · 2024: $893 · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,319 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,319.38 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $343.80 | 2023-2025 | |
| Janssen Biotech, INC. | $331.87 | 2023-2025 | Tremfya |
| Amgen INC. | $289.39 | 2022-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $271.77 | 2023-2025 | |
| Incyte Corporation | $165.18 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $162.21 | 2023-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $132.55 | 2024-2025 | Nemluvio, Aklief |
| Organon LLC | $115.64 | 2025 | Vtama |
| Lilly USA, LLC | $105.65 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Krystal Biotech INC | $100.63 | 2023 | Vyjuvek |
| Arcutis Biotherapeutics, INC. | $97.09 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $81.33 | 2022-2024 | Adbry |
| Regeneron Healthcare Solutions, INC. | $80.60 | 2023-2025 | Dupixent |
| Dermavant Sciences, INC. | $67.48 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $63.65 | 2023-2024 | Winlevi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $51.62 | 2024-2025 | Cabtreo, Jublia, Arazlo |
| Mayne Pharma Commercial LLC | $40.44 | 2023-2024 | |
| Genzyme Corporation | $31.39 | 2023 | |
| Pfizer INC. | $16.87 | 2023 | |
| Ucb, INC. | $16.12 | 2025 | Bimzelx |
| Verrica Pharmaceuticals INC. | $14.79 | 2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $14.62 | 2023 | Valchlor |
| Almirall LLC | $14.59 | 2023 | Seysara |
| Lnhc, INC | $14.30 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Cittone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.